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Research
In the United States the population of persons
age 65 years and older is projected to increase
2-fold to 75 million in the next 30 years, and a
concomitant upsurge in the number of indi-
viduals with dementia is expected (U.S.
Census Bureau 2000a, 2000b). Cognitive
decline, a risk factor for dementia, may be a
transition stage spanning normal cognition
and onset of diseases associated with dementia
(Bischkopf et al. 2002; Burns and Zaudig
2002; Pratico et al. 2002).
Lead has long been recognized as a neuro-
toxicant; the associations between lead and
cognitive impairment among workers in lead-
related industries and poorer cognitive devel-
opment in children have been well reproduced
(Barth et al. 2002; Bleecker et al. 1997;
Lanphear et al. 2000). The few studies that
have been conducted among low-level lead-
exposed older adults have generally reported
inverse associations between lead burden and
cognitive function (Muldoon et al. 1996;
Nordberg et al. 2000; Payton et al. 1998;
Weisskopf et al. 2004; Wright et al. 2003).
With half-life estimates ranging from 5 to
20 years for cortical bone, and more than
1 year for trabecular bone (Hu et al. 1998;
Kim et al. 1997), lead levels in bone may bet-
ter reflect long-term body burden of lead
than blood lead, which has a half-life of
approximately 30 days (Hu 2001). In addi-
tion, bone lead measures correlate well with
measures of cumulative external lead levels
and integrated blood lead levels, two
commonly used indices of cumulative lead
exposure (Bleecker et al. 1997). 
Iron metabolism may play a critical role in
neurodegenerative processes (Lee et al. 2006;
Todorich and Connor 2004). Although iron is
vital for cellular processes, plasma iron which is
not bound to transferrin may be toxic. This
nontransferrin-bound iron represents the por-
tion of body iron likely to cause cellular oxida-
tive damage, a purported mechanism in the
pathogenesis of neurodegenerative diseases,
and serve as a catalyst in the neuronal produc-
tion of free radicals (Eaton and Qian 2002;
Samson and Nelson 2000). Two variants in
the hemochromatosis (HFE) gene, C282Y and
H63D, are commonly found in the U.S.
population, especially among whites, and are
associated with hereditary hemochromatosis, a
disease of iron overload. Several recent studies
have reported an association between these
HFE polymorphisms and neurodegenerative
diseases such as Alzheimer disease (Berlin et al.
2004; Moalem et al. 2000; Sampietro et al.
2001). Furthermore, carriers of these polymor-
phisms who do not have clinical signs of iron
overload are observed to have higher levels of
nontransferrin-bound iron in addition to body
iron measures higher than wild-types (Adams
et al. 2005; Beutler et al. 2003; Datz et al.
1998; de Valk et al. 2000; Garry et al. 1997). 
These studies have led to a growing inter-
est in the interaction of iron and lead metabo-
lism in the process of neurodegeneration. As
HFE variant alleles are associated with neu-
rodegenerative processes similar to those seen
in lead toxicity, and the presence of iron
enhances the oxidative effects of lead
(Adonaylo and Oteiza 1999), HFE variant
alleles may magnify the neurologic damage
caused by lead. Therefore, we examined the
modifying effect of the HFE alleles on the
association between body lead burden and
change in performance on the Mini-Mental
State Examination (MMSE), a test of global
cognitive function, in a cohort of older,
community-dwelling men.
Materials and Methods
Participants in the current study were drawn
from the Normative Aging Study (NAS), a
community-based, prospective cohort study
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BACKGROUND: As iron and lead promote oxidative damage, and hemochromatosis (HFE) gene
polymorphisms increase body iron burden, HFE variant alleles may modify the lead burden and
cognitive decline relationship. 
OBJECTIVE: Our goal was to assess the modifying effects of HFE variants on the lead burden and
cognitive decline relation in older adults.
METHODS: We measured tibia and patella lead using K-X-ray fluorescence (1991–1999) among
participants of the Normative Aging Study, a longitudinal study of community-dwelling men from
greater Boston. We assessed cognitive function with the Mini-Mental State Examination (MMSE)
twice (1993–1998 and 1995–2000) and genotyped participants for HFE polymorphisms. We esti-
mated the adjusted mean differences in lead-associated annual cognitive decline across HFE geno-
type groups (n = 358).
RESULTS: Higher tibia lead was associated with steeper cognitive decline among participants with at
least one HFE variant allele compared with men with only wild-type alleles (p interaction = 0.03),
such that a 15 µg/g increase in tibia lead was associated with a 0.2 point annual decrement in
MMSE score among HFE variant allele carriers. This difference in scores among men with at least
one variant allele was comparable to the difference in baseline MMSE scores that we observed
among men who were 4 years apart in age. Moreover, the deleterious association between tibia lead
and cognitive decline appeared progressively worse in participants with increasingly more copies of
HFE variant alleles (p-trend = 0.008). Results for patella lead were similar.
CONCLUSION: Our ﬁndings suggest that HFE polymorphisms greatly enhance susceptibility to lead-
related cognitive impairment in a pattern consistent with allelelic dose. 
KEY WORDS: cognitive decline, epidemiology, HFE, lead, longitudinal studies, neuropsychologic
tests. Environ Health Perspect 115:1210–1215 (2007). doi:10.1289/ehp.9855 available via
http://dx.doi.org/ [Online 10 May 2007]initiated in 1963 at the Veterans Affairs (VA)
Outpatient Clinic in Boston to examine
factors related to healthy aging (Bell et al.
1972). The cohort consisted of 2,280 men
21–81 years of age at the time of enrollment
(1963–1968) who had successfully completed
a screening process to ensure participants were
free of known chronic medical conditions.
Most cohort members were of northern
European descent. Overall, their smoking and
alcohol consumption patterns were similar to
men of comparable age in the U.S. popula-
tion. Every 3–5 years, study participants were
asked to undergo extensive evaluations includ-
ing medical and physical examinations and
laboratory tests. They also completed ques-
tionnaires on smoking history, diet, and other
factors potentially related to aging and health.
To date, the annual attrition due to all causes
has been less than 1%, and more than 80%
have responded to mailed questionnaires sup-
plementing on-site examinations (Hu et al.
1996). This study has been approved by the
Human Subjects Committees of the Boston
VA Medical Center, the Brigham and
Women’s Hospital, and the Harvard School
of Public Health. 
Study population. Beginning in 1991,
bone lead measurements were taken using
K-X-ray fluorescence (KXRF) among active
participants who gave written informed con-
sent. In 1993, cognitive function assessments
were initiated. At the time of the present study,
1,055 study participants had completed at least
one cognitive assessment; whereas 540 men
had two or more assessments. The first and
second cognitive assessments were on average
3.2 years apart. Of the men with two cognitive
measures, 420 had at least one bone lead mea-
surement. In 2000, NAS participants (n = 730)
were genotyped for two HFE polymorphisms
based on archived blood samples. In all, our
analyses included the 358 men with at least
two cognitive assessments, complete covariate
information, HFE genotyping data, and at
least one measure of bone lead.
Bone lead KXRF measurement. In vivo
bone measurements were taken using a
K-X-ray fluorescence (KXRF) instrument
(ABIOMED, Inc., Danvers, MA) at the mid-
tibia (shin bone) and the patella (knee cap
bone) (Aro et al. 2000). The sites were chosen
to be representative of the two predominant
bone types: cortical bone (tibia) and trabecular
bone (patella). These measurements had units
of micrograms of lead per gram bone mineral.
The bone measurement taken closest in time
to the baseline cognitive assessment served as a
proxy for tissue lead burden. The instrument
also provides an estimate of the uncertainty for
each measurement equivalent to the standard
deviation of repeated measurements. Lead esti-
mates with uncertainty values > 10 µg/g for
tibia and > 15 µg/g for patella were excluded as
unreliable, a standard protocol in analyses of
bone lead (Hu et al. 1998). Negative estimates
of bone lead concentrations may occur for lead
values close to zero. As recoding the negative
values to the minimum detectable limit may
induce bias and reduce efﬁciency in the statisti-
cal analyses, KXRF-measured bone lead con-
centration estimates were used in the analysis
without recoding (Kim et al. 1997).
HFE genotyping. We genotyped parti-
cipants for both the C282Y and H63D poly-
morphisms of the HFE gene (GenBank
accession no. Z92910; http://www.ncbi.nlm.
nih.gov/sites/entrez) using archived blood.
Puregene DNA isolation kits (Gentra Systems,
Inc., Minneapolis, MN) were used to extract
the DNA from the blood sample. The H63D
polymorphism was genotyped by polymerase
chain reaction (PCR) followed by restriction
fragment length polymorphism (RFLP) analy-
sis as previously described (Cardoso et al.
1998; Wright et al. 2004). Similarly, the
C282Y polymorphism was genotyped by sepa-
rate PCR and RFLP procedures (Cardoso et al.
1998; Feder et al. 1996). 
As a quality control measure, 10% of sam-
ples were randomly selected and run in dupli-
cate. Genotypes were also determined on
control blood known to be from persons
homozygous for the wild-type genotype and
heterozygous and homozygous for each HFE
variant genotype. The full data set was
anonymized after genotyping to protect our
study members and to conform to current
Institutional Review Board policies.
Assessment of cognitive function. One of
the tests included in the cognitive assessment
battery was the MMSE, a global examination
of cognitive function that assesses orientation,
immediate and short-term recall, verbal and
written skills, and attention and ability to fol-
low commands (Crum et al. 1993; Folstein
et al. 1975). The test is commonly used in 
epidemiologic studies to evaluate cognitive sta-
tus (Farmer et al. 1995; Izaks et al. 1995;
Knopman et al. 2003). Scores range from 0 to
30, with higher score denoting better cognitive
performance, although in our analysis the
highest possible score was 29 because of dele-
tion of the question “What county are we in?”
from our tally. Other studies have reported
that most Massachusetts residents do not know
in which county they reside as counties in
Massachusetts do not have strong governmen-
tal function (Tombaugh and McIntyre 1992). 
Statistical analysis. Because of small sam-
ple sizes in some strata of HFE genotypes, we
classified HFE genotypes in two different
manners: binary [wild-type (having only HFE
wild-type alleles), any HFE variant allele]; and
dose (wild-type, one HFE variant allele, two
HFE variant alleles). Our measure of change
in cognition was the average annual rate of
decline in MMSE score, defined as (MMSE
score at second visit – MMSE score at baseline
visit)/(years between assessments), for each
participant. 
We analyzed lead levels in tibia and patella
separately. To assess effect modiﬁcation, we ﬁt-
ted multiple linear regression models of average
annual rate of decline in MMSE score, in
which we included a term for the lead bio-
marker, indicator variables for the HFE geno-
type classification, and cross-product terms
between HFE genotype and lead biomarker,
along with terms for age, years of education,
smoking status (current, never, past), pack-years
smoked, nondrinker, alcohol consumption
(grams/day), English as ﬁrst language (yes, no),
computer experience (yes, no) and diabetes
(diagnosis or fasting glucose > 126 mg/dL).
Values of covariates used in the analyses were
those reported at the baseline MMSE assess-
ment. Stroke and Alzheimer disease predict
MMSE score, but as so few men in our study
population had such conditions, these condi-
tions were not considered in our analyses. We
assessed the linearity of the association between
lead and annual rate of cognitive decline within
class of HFE genotype by fitting a penalized
spline for the lead biomarker and adjusting for
covariates using the generalized additive models
function in R software (http://www.r-project.
org/). A penalized spline is a technique for ﬂexi-
bly modeling dose–response by dividing the
range of exposure into intervals, and ﬁtting a
separate cubic polynomial within each interval.
A penalty term is added to the log likelihood
that is proportional to how “wiggly” the result-
ing dose–response curve is, which prevents
excessive nonlinearity (Wood and Augustin
2002). The optimal degree of smoothing was
determined by the generalized cross-validation
criterion, which is, in practice, an approxima-
tion of Akaike’s information criterion (Wood
and Augustin 2002).
To assess whether participants with
C282Y and H63D alleles have different lead-
associated cognitive changes, we also con-
ducted exploratory analyses to evaluate the
association of lead on cognitive decline by
HFE genotype groups (e.g., wild-type, H63D
homozygotes, C282Y heterozygotes). Finally,
to assess the robustness of our results, we ﬁrst
restricted our analyses to white participants,
then repeated the analyses after removing out-
liers identiﬁed by the generalized extreme stu-
dentized deviation (ESD) method (Rosner
1983). All statistical analyses were conducted
using SAS (version 8.2; SAS Inc., Cary, NC)
and R version 2.1.1. We used partial F-tests
and likelihood ratio tests for statistical
hypothesis testing. The p-value of signiﬁcance
was < 0.05.
Results
Median concentrations of bone lead in our
study population were 19 and 23 µg/g for tibia
HFE polymorphisms and lead on cognitive decline
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younger, more educated, native English speak-
ers, or who had computer experience on aver-
age had lower bone lead levels (Table 1). Bone
lead concentrations were slightly higher among
men with lower baseline cognitive scores.
Thirty-six percent of men had at least one
HFE variant allele. Both genotype distributions
conformed to Hardy-Weinberg expected fre-
quencies (C282Y: χ2 =0.53, p = 0.47; H63D:
χ2 =0.18, p = 0.67). Nine participants in our
population were heterozygous for both
C282Y and H63D polymorphisms (known as
compound heterozygotes). Although bone
lead levels appeared higher in the four partici-
pants who were C282Y homozygotes, these
measures were not signiﬁcantly different than
the bone lead levels among wild-types.
Characteristics of men with only HFE wild-
type alleles were similar to those of variant
allele carriers with the exception of report of
computer experience (Table 2). Compared
with men in the larger NAS cohort who had
only one MMSE score, men in our study pop-
ulation had similar average baseline MMSE
scores and only slightly lower mean bone lead
levels (data not shown). The distribution of
HFE genotypes was also similar in these two
groups. Men with and without bone lead
measures had similar baseline characteristics,
distribution of HFE genotypes, and MMSE
scores (data not shown). 
The average annual rate of decline in
MMSE scores was modestly though not sig-
niﬁcantly worse among HFE variant allele car-
riers than among men with only HFE
wild-type alleles {difference in annual rate of
change: –1.77 points/year [95% confidence
interval (CI), –3.88 to 0.35]}, results not
shown). Higher tibia lead was associated with
a steeper decline in MMSE scores among par-
ticipants with at least one HFE variant allele
compared with wild-types (p = 0.03; Table 3,
model 1). Among participants with any HFE
variant allele, an interquartile range (IQR)
increment in tibia lead (15 µg/g) was associ-
ated with a 0.22-point annual decrement in
MMSE score (95% CI, –0.39 to –0.05). This
annual change in MMSE score among variant
allele carriers was approximately equivalent to
the difference in baseline MMSE scores
between men in our study population who
were 4 years apart in age. In contrast, although
tibia lead level was associated with decline in
MMSE score among wild-types as well, this
association was smaller in magnitude and not
statistically significant. We used covariate-
adjusted penalized splines to explore the lin-
earity of the association between tibia lead
level and change in MMSE score by HFE
genotype, as shown in Figure 1. Even though
the association of lead burden with cognitive
decline among men with only HFE wild-type
alleles appeared linear (optimal degree of
smoothing: 1, p = 0.72), the association
appeared curvilinear, speciﬁcally, steeper with
greater lead burden in the variant allele carri-
ers. The test for deviation from linearity for
the tibia lead–cognitive change association
among the variant allele carriers was nearly sig-
niﬁcant (optimal degree of smoothing: 1.68,
p = 0.08), suggesting that, among variant allele
Wang et al.
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Table 1. Baseline characteristics of study participants (n = 358) by bone lead measures [median µg/g (IQR)].
Tibia lead Patella lead
Age (years)
< 65 15 (9–20) 18 (13–27.5)
65–70 20 (14–28) 25 (17–34)
≥ 71 25 (18–35) 28 (17–52)
Education
Never ﬁnished high school 30 (14–36) 33.5 (23–46)
High school graduate 21 (14–29) 27 (16–44)
Some college 19 (13–28) 25 (15–37)
College graduate 17 (11–22) 19 (13–29)
Smoking status
Never 17 (11–27) 21.5 (13–33)
Former 20 (14–29) 24 (16–36)
Current 19 (13.5–23.5) 27 (15–34)
Alcohol consumption
Yes 19 (13–26) 23 (15–35)
No 20 (12.5–30) 24 (17–36)
History of diabetesa
Yes  23 (14–35) 27 (17–38)
No 19 (13–27) 23 (15–35)
English as ﬁrst language
Yes 19 (12–27) 22.5 (15–34)
No 24 (15–30) 27 (17–39)
Computer experience
Yes 15 (10–22) 20 (13.5–30)
No 21 (14–30) 26 (16–39)
Baseline MMSE scoreb
< 26 20.5 (13–30) 26.5 (15–39)
26–27 21 (13.5–27.5) 24 (15–38)
≥ 28 16 (11–22.5) 21 (15–31)
HFE genotype
Wild-type (n = 228) 19 (13–29) 24 (15–37)
One or more HFE variant alleles 19.5 (12–26) 22 (14–34)
H63D heterozygotes (n = 69) 20.5 (11.5–25.5) 22 (14–33)
H63D homozygotes (n = 8) 17 (12.5–27) 23.5 (13–34)
C282Y heterozygotes (n = 40) 17 (13–21) 22 (14–34)
C282Y homozygotes (n = 4) 32.5 (21–39) 39 (16–61.5)
Compound heterozygotes (n = 9) (C282Y and H63D alleles) 15 (11–20) 21 (12–27)
IQR, interquartile range. 
aHistory of diabetes deﬁned as having reported diagnosis of diabetes or having fasting glucose above 126 mg/dL. bHighest
possible MMSE score in our analysis was 29 because of deletion of the question “What county are we in?”
Table 2. Baseline characteristics of participants by HFE genotype (n = 358). 
HFE wild-type (n = 228) HFE variant allele (n = 130)
Age [median years (IQR)] 67.2 (62.6–71.8) 67.7 [63.7–71.3]
Education [n (%)]
Never ﬁnished high school 19 (8.3) 9 (6.9)
High school graduate 64 (28.1) 36 (27.7)
Some college 64 (28.1) 33 (25.4)
College graduate 81 (35.5) 52 (40.0)
Smoking status [n (%)]a
Never 76 (33.3) 46 (35.4)
Former 138 (60.5) 81 (62.3)
Current 14 (6.1) 3 (2.3)
Alcohol consumption [median g/day (IQR)] 5.8 [0.4–18.7) 6.0 [0–16.7)
History of diabetesb [n (%)] 24 (10.5) 13 (10.0)
English as ﬁrst language [n (%)] 199 (87.3) 118 (90.8)
Computer experience [n (%)] 87 (38.2) 65 (50.0)
Patella lead [median µg/g (IQR)] 24 (15, 37) 22 (14, 34)
Tibia lead [median µg/g (IQR)] 19.0 (13, 29) 19.5 (12, 26)
Baseline MMSE score [median (IQR)]c 27 (25, 28) 27 (26, 28)
IQR, interquartile range. 
aPercentages may not add up to 100 because of rounding. bHistory of diabetes deﬁned as having reported diagnosis of
diabetes or having fasting glucose above 126 mg/dL. cHighest possible MMSE score in our analysis was 29 because of
deletion of the question “What county are we in?”carriers, a unit increase in lead burden may be
associated with disproportionately greater cog-
nitive decline at high lead burden than at low
lead burden.
Interestingly, the detrimental association
between tibia lead and decline in MMSE was
progressively larger with increasing number of
HFE variant alleles: each IQR increment in tibia
lead was associated with a –0.02-point/year
change in MMSE score among wild-types,
–0.14-point/year change among men with one
HFE variant allele, and –0.63 point/year
change among men with two HFE variant alle-
les (p < 0.01, Table 3, model 2). The pro-
nounced difference in lead-associated cognitive
decline between men with two variant alleles
and men with only wild-type alleles was signiﬁ-
cant (p < 0.01, Table 3, model 2). This differ-
ence in change in MMSE scores among
participants with two HFE variant alleles was
comparable to the difference in baseline
MMSE scores that we observed among men
who were 11 years apart in age. 
We also examined the modiﬁcation of the
lead association with annual change in MMSE
score by HFE genotype groups. The magni-
tudes of effect modiﬁcation among H63D het-
erozygotes and C282Y heterozygotes were very
similar to the magnitude of effect modiﬁcation
among one variant allele carriers. Similarly, the
results for H63D homozygotes and C282Y
homozygotes were similar to the results for two
variant allele carriers (results not shown).
Overall, the associations pertaining to
patella lead were similar to although smaller in
magnitude than those pertaining to tibia lead
(results not shown). Results from analyses in
which we excluded extreme values of bone lead
were also similar, as were results in analyses in
which we restricted the study population to
whites (results not shown). 
Discussion
In our population of older men, the deleterious
association between long-term lead burden and
rate of decline in cognitive function was signiﬁ-
cantly worse among HFE variant allele carriers
than among wild-types. Furthermore, the
detrimental association of lead with cognitive
decline was magniﬁed among participants with
a greater number of either variant alleles
(H63D or C282Y); the largest drop in MMSE
scores associated with lead burden was
observed in men carrying two variant alleles.
Of note, the magnitude of effect modiﬁcation
was linked to number and not to type of HFE
variant alleles. Our study is the ﬁrst to provide
evidence that the neurodegenerative effects of
these variants during aging may be in part due
to genetic susceptibility to non-iron metals
such as lead.
Several studies have addressed cognitive
function among adults who experienced
chronic low-level lead exposure (Muldoon
et al. 1996; Weisskopf et al. 2004; Wright
et al. 2003). Among the studies that used bone
lead measures, tibia lead was more strongly
associated with cognitive decline than were
patella and blood leads (Payton et al. 1998;
Weisskopf et al. 2004), suggesting that lead in
tibia serves as a superior proxy for effective lead
dose in the brain. As lead in the tibia has a sub-
stantially longer half-life than lead in the
patella or blood (Hu 1998), these results indi-
cate that long-term, chronic lead exposure may
be more predictive of cognitive changes.
Interestingly, the strongest interaction between
lead and HFE variant alleles in our study was
also observed with tibia lead measures. 
We are not aware of any other study that
has evaluated the modifying effect of the HFE
genotype on the association between lead and
change in cognitive function. The HFE pro-
tein appears to regulate metal transport across
cell membranes (Chung and Wessling-Resnick
2003), although its role in transporting iron
and non-iron divalent metals across the blood
brain barrier is unknown. Two common poly-
morphisms in the HFE gene, the C282Y and
the H63D, have been implicated in hereditary
hemochromatosis, a disease associated with
excess iron absorption (Feder et al. 1996;
Hanson et al. 2001). In addition, persons who
carry the HFE variant alleles but who lack clin-
ical signs of hemochromatosis disease are
reported to have signiﬁcantly higher values of
serum iron, transferrin saturation, and non-
transferrin-bound iron than individuals with
only HFE wild-type alleles (Beutler et al. 2003;
Datz et al. 1998; Garry et al. 1997; Moura
et al. 1998). HFE polymorphisms have also
been reported to affect lead uptake (Bannon
et al. 2003; Barton et al. 1994; Onalaja and
Claudio 2000; Wright et al. 2004). In our
analysis, men who were homozygous for
C282Y appeared to have higher bone lead bur-
den than men with other HFE genotypes,
although we were not able to detect a statisti-
cally signiﬁcant difference with our small sam-
ple size of C282Y homozygotes. This subject
matter merits further examination in larger
study populations. 
Although the relationship between HFE
alleles and neurodegenerative diseases is not
fully established, several recent studies have
found positive associations between HFE vari-
ant alleles and Alzheimer disease. Researchers
have reported the C282Y and H63D polymor-
phisms to be significantly more prevalent in
subjects with Alzheimer disease compared with
controls, and that persons with Alzheimer dis-
ease and HFE variant alleles were on average
6 years younger at the time of diagnosis than
individuals with Alzheimer disease but with
only the wild-type alleles (Moalem et al. 2000;
Pulliam et al. 2003; Sampietro et al. 2001).
Another study also observed earlier age of onset
of Alzheimer disease but only among H63D
homozygotes (Berlin et al. 2004). In contrast,
others have found no association between HFE
alleles and Alzheimer disease (Berlin et al. 2004;
Guerreiro et al. 2006). The discrepancies across
HFE polymorphisms and lead on cognitive decline
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Table 3. Association with an interquartile (15 µg/g) increase in tibia lead biomarkers on change in MMSE
score by class of HFE genotype. 
Unadjusted mean  Adjusteda mean 
Model/class of  difference in annual rate of  difference in annual rate of  p-Value p-Value
HFE genotype change in MMSE (95% CI) change of MMSE (95% CI) interaction trend
Model 1: binary  0.03b NA
Wild-type –0.02 (–0.10 to 0.05) –0.02 (–0.10 to 0.07)
Any HFE variant allele –0.23 (–0.40 to –0.07) –0.22 (–0.39 to –0.05)
Model 2: dose < 0.01c < 0.01
Wild-type –0.02 (–0.10 to 0.05) –0.02 (–0.10 to 0.07)
One HFE variant allele –0.15 (–0.33 to 0.03) –0.14 (–0.33 to 0.04)
Two HFE variant alleles –0.62 (–1.03 to –0.22) –0.63 (–1.04 to –0.21)
NA, not applicable. 
aAdjusted for age, years of education, nonsmoker, former smoker, pack-years, nondrinker, alcohol consumption, English
as first language, computer experience, and diabetes. bp-Value for tibia lead and any HFE variant allele interaction.
cp-Value for tibia lead and two HFE variant alleles interaction.
Figure 1. Exploration of nonlinear association of
tibia lead concentration with annual rate of cogni-
tive decline, by class of HFE genotype. The lines
indicate curvilinear trends estimated from the
penalized spline method. Among HFE wild-types,
the optimal degree of smoothing was 1, meaning
that the association between tibia lead and annual
cognitive decline was nearly linear, but among
variant allele carriers, the association tended to
deviate from linearity (p = 0.08), with an optimal
1.68 degree of smoothing. The model was adjusted
for age, years of education, nonsmoker, former
smoker, pack-years, nondrinker, alcohol consump-
tion, English as first language, computer experi-
ence, and diabetes.
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HFE variant allelestudies may reﬂect that HFE polymorphisms
do not independently impart cognitive risk but
instead enhance the neurotoxicity of agents
such as lead. Interestingly, although the C282Y
and H63D functional polymorphisms may dif-
ferentially alter iron and divalent metal metabo-
lism (Bomford 2002; Lyon and Frank 2001;
Townsend and Drakesmith 2002), we observed
these two polymorphisms to have comparable
magnitudes of effect modiﬁcation on the rela-
tion between lead and cognitive decline.
It is not known how the HFE variant alleles
may accelerate cognitive decline in the presence
of lead. Lead and free iron are independently
capable of promoting oxidative damage, a pur-
ported mechanism in the pathogenesis of
neurodegenerative disease (Jellinger 1999;
Jenner 1993; Samson and Nelson 2000;
Winterbourn 1995). In vitro studies have sug-
gested synergistic oxidative effects between lead
and iron; lead appears to increase lipid oxida-
tion in the presence of iron (Adonaylo and
Oteiza 1999). Therefore, our findings may
reﬂect the complex relationship between iron
and lead metabolism where the metals interact
to further increase damage and, consequently,
cognitive decline. Unfortunately, we were not
able to measure body iron status or magnitude
of oxidative stress for our study population.
Our current ﬁndings are an interesting jux-
taposition to our previous report in which
HFE variant alleles were associated with lower
levels of internal lead dose biomarkers in the
same cohort (Wright et al. 2004). If the HFE
variant alleles affect cognition predominantly
by lowering lead accumulation in the body tis-
sues, one might expect the variant alleles to be
associated with better cognitive performance.
Instead, we found a suggestive association
between HFE variant alleles and poorer cogni-
tive function that is consistent with the prior
reports linking HFE variant alleles to neurode-
generation. In addition, because the HFE vari-
ant alleles are not known to affect the relation
of lead levels in tibia to lead levels in the brain,
one would anticipate similar magnitudes of
change in MMSE scores per unit increase in
body lead burden among wild-types compared
with variant allele carriers. Our data suggest
quite the opposite, indicating that HFE variant
alleles augment the toxicity of lead that is
absorbed.
There were several limitations to this study.
Although the associations observed were sig-
niﬁcant, it is essential to attempt to reproduce
such associations in larger populations. The
mean interval between the two cognitive tests
was 3.2 years. With a longer interval between
testing or with additional MMSE assessments,
we may be able to better describe the relation-
ship between lead and cognitive changes by
HFE genotype.
As with any aging cohort, there was a
potential for selection bias mainly because of
differential attrition and survival. We were
somewhat reassured, as the lead biomarker lev-
els and ﬁrst MMSE scores in persons who had
completed only baseline cognitive assessment
were similar to those found in our study popu-
lation. The frequencies of HFE genotypes
were also similar in the two groups. Moreover,
baseline characteristics and MMSE scores did
not differ in men with and without bone lead
measures.
The potential for misclassiﬁcation should
be considered. Although there may have been
some measurement error in our bone lead data,
such errors would most likely be nondifferen-
tial, and thus, bias our association estimates
toward the null. It is possible that the modify-
ing effects observed were caused by other poly-
morphisms in the HFE gene or polymorphisms
in a proximal gene that is in tight linkage dise-
quilibrium with these HFE polymorphisms,
although we believe this is unlikely, as we did
not find other genes known to regulate iron
metabolism in this genomic region. 
As in any observational study, confounding
is a concern. We accounted for known strong
predictors of cognitive function. As only one
participant had suffered a stroke and none had
been diagnosed with Alzheimer disease, we did
not adjust for these factors in our ﬁnal model.
Of the men in our study population, 99%
were white, making population stratification
an unlikely confounder. Overall, crude and
adjusted comparisons of MMSE change were
similar, suggesting that strong confounding
from an unmeasured source is unlikely.
The MMSE is widely used to screen for
dementia and has frequently been used to
assess cognitive status and track longitudinal
changes in cognitive function (Farmer et al.
1995; Izaks et al. 1995; Knopman et al.
2003). However, it is a relatively easy test for
which a learning effect has been reported
(Jacqmin-Gadda et al. 1997). A low degree of
variability in MMSE scores among more
highly educated persons is often observed
(Crum et al. 1993). Therefore, the MMSE
may have had low sensitivity in detecting cog-
nitive impairment in our participants. Despite
these limitations, the MMSE is among the
most extensively characterized and most
widely used tests of cognitive status for older
adults, and performs with a reasonable degree
of reproducibility and validity. Past studies
have found high correlations between MMSE
scores and scores on other well-described cog-
nitive tests, such as the Blessed Information-
Memory-Concentration test and reasonable
sensitivity and speciﬁcity in delineating indi-
viduals with and without dementia (Crum
et al. 1993; Stuss et al. 1996; Tombaugh and
McIntyre 1992). Finally, persons with mild
cognitive impairment are found to have signif-
icantly worse MMSE scores than cognitively
normal individuals (Bennett et al. 2002). 
Although we were not yet able to assess
development of dementia in our population,
cognitive decline is a strong predictor of subse-
quent dementia. Cognitively impaired individ-
uals have a 10–15% annual risk of developing
dementia compared with a 1–2% annual risk
among healthy controls (Bischkopf et al. 2002;
Knopman et al. 2003; Morris et al. 2001).
Cognitive impairment has also been associated
with a 3.1- to 5-fold increase in risk of develop-
ing Alzheimer disease, the most common cause
of age-related dementia (Tuokko et al. 2003). 
Our ﬁndings suggest that cumulative lead
exposure may be particularly detrimental to the
cognitive well-being of HFE variant allele carri-
ers as they age. Given the high prevalence of
variant allele carriers in North American and
European populations and the long retention
of lead in the body, our results indicate that
lead-related cognitive impairment experienced
by a large subset of older adults is likely
more substantial than currently recognized.
Although these early cognitive changes may
have slight consequences on many affected
individuals, these small decrements pose a
major public health concern, translating into a
much larger proportion of older individuals
who are considered clinically impaired, a soci-
etal burden that is projected to grow substan-
tially, given that older persons make up one of
the fastest growing segments of our population
(U.S. Census Bureau 2000a, 2000b). Our
findings provide insight on the mechanisms
and pathways of cognitive decline. As there is
currently no cure for dementia, elucidating the
biological mechanisms may facilitate the devel-
opment of preventive measures and treatments
to hinder the rate of cognitive decline. As long-
term chronic lead exposure appears to be most
detrimental to cognitive health in the later
years, our ﬁndings stress the continued impor-
tance of public health interventions aimed at
reducing occupational and environmental
exposure to lead in younger populations
including lead abatement efforts and lead
exposure prevention programs.
In summary, we have found the HFE
polymorphisms to significantly modify the
association between lead burden and the rate
of cognitive decline. Persons with more copies
of HFE variant alleles experienced greater
cognitive decline per unit increase in bone
lead biomarker level.
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